Business Wire

NATS Partners with Quintiq to Solve Complex Planning Puzzle of 1,500 Employees Handling More Than 7,000 Flights Daily


NATS, the UK’s leading ANSP (air navigation service provider), has chosen Quintiq, a Dassault Systèmes brand, to overcome its rostering challenges in a highly complex planning environment. NATS manages air traffic over the UK as well as the eastern part of the Atlantic Ocean and provides ATC (air traffic control) services to 13 UK airports. With an operational workforce of 1,500 handling an average of 5,000 to 7,000 flights daily, NATS needs to ensure the allocation of the right people with the right skills at the right time. To achieve this NATS sought a solution to integrate rosters and resources to increase accuracy and make the planning process more efficient.

NATS Chief Information Officer Gavin Walker, describes the company’s current planning challenges, “Rosters follow detailed labour rules and regulations; we’re using different planning systems, many of them requiring manual input, so it’s a time-consuming process.”

“The new Quintiq planning system can support NATS’ business requirements, which includes adherence to the many layers of rostering rules found in our regulated industry. Our requirements are to perform the short-term planning up to nine months ahead as well as support the medium-term planning up to 24 months ahead. Meanwhile, the software allows fast re-planning, respecting those labour rules and regulations, should last-minute disruptions occur. The optimiser function releases planners from time-consuming work every time something changes, so that they can focus their expertise exactly where and when it’s needed.”

The Quintiq solution will be used to plan for air traffic controller officers (ATCOs), air traffic service assistants (ATSAs), and for support personnel. Employees also have non-operational duties such as project meetings and training that need to be incorporated into the rosters.

Gavin elaborates, “We chose Quintiq because they were able to accommodate our specific labour and safety regulations, training, holidays, simulation work and overtime management. The software can be configured to achieve this.”

In addition to the core roster functionality, NATS was also looking to take employee preferences into consideration with a system that can be accessed from home or via mobile. The Quintiq answer to this is a mobile application, which allows interactive communication between ATCOs or ATSAs and the planners when creating new requests or checking the status of existing requests. For employees, this means a single point of contact for all shift-related communications and tasks. Next to this, the Quintiq planning and optimisation software also provides a holistic view of resource demand and supply, reporting and scenario planning.

Rob van Egmond, CEO of Quintiq, is proud of NATS’ confidence in Quintiq, “With a highly specialised workforce in a highly regulated industry, NATS presented just the kind of complex puzzle we at Quintiq live to solve. We’ve recently made great inroads in the aviation sector where we serve some of the largest players: DFS, Fraport, Copenhagen Airports, Virgin Atlantic Airways and now NATS. We look forward to driving business efficiency across multiple planning horizons for NATS.”

About NATS

NATS is the UK's leading provider of air traffic control services. It operates out of Swanwick in Hampshire, England and Prestwick in Ayrshire, Scotland. Each year, it handles 2.3 million flights and 250 million passengers in the UK airspace. Besides providing services to 13 UK airports and managing all upper airspace in the UK, it also provides services across Europe, the Middle East, Asia and North America. Find out more at

About Quintiq

Every business has its supply chain planning puzzles. Some of those puzzles are large, some are complex and some seem impossible to solve. Since 1997, Quintiq has been solving each of those puzzles using a single supply chain planning and optimisation software. Today, approximately 12,000 users in over 80 countries rely on Quintiq software to plan and optimise workforces, logistics and production. Quintiq is part of Dassault Systèmes (Euronext Paris: #13065, DSY.PA) and has headquarters in the Netherlands and the USA, and offices around the world.

For more information, visit or follow Quintiq on Twitter, Facebook, LinkedIn and YouTube.

Contact information

North America Enquiries
Katie Kennedy
Gregory FCA
Tel: +1 610 228 2128
EMEA Enquiries
Richard Ratcliffe
Weber Shandwick
+44 207 067 0846

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Seoul Semiconductor’s SunLike Series LEDs Win Product of the Year Award from Elektronik Magazine23.3.2018 21:28Tiedote

Seoul Semiconductor, a global innovator of LED products and technology, announced on March 23rd that its SunLike Series natural spectrum LED product won the Gold Award at the Elektronik Product of the Year 2018 Awards, hosted by Elektronik (, a leading German electronics publication. This press release features multimedia. View the full release here: Product of the Year Award from Elektronik Magazine (SunLike) (Photo: Business Wire) As a publication specializing in electrical and electronic components, “Elektronik” is a prestigious magazine with an illustrious history and the largest number of subscribers in Germany. Over the past 20 years, they have conducted annual surveys among their subscribers to find the “most creative and innovative products.” Based on these survey results, Elektronik selects the top product that with the most impact in its corresponding field, and confers the awards accordingl

Elliott Welcomes Imminent Bezeq Board Overhaul and New Era for Strong Independent Governance23.3.2018 19:05Tiedote

Elliott Advisors (UK) Limited (“Elliott”), which advises funds which collectively hold a significant economic interest in Bezeq The Israeli Telecommunication Corporation Ltd. (“Bezeq” or the “Company”), welcomes the proposed governance reforms announced by Bezeq last night. In its initial letter to Bezeq Interim Chairman David Granot, dated January 16, 2018, Elliott outlined the urgent need to address the Company’s serious corporate governance issues, and called for changes at the Board level that result in “the right mixture of expertise, independence and integrity for the future.” Elliott stated then, and reiterates now, its belief that “there is significant value to be unlocked if the right steps are taken to improve its corporate governance.” Bezeq has strong business fundamentals, an exemplary workforce, and great potential. Following yesterday’s announcement, Elliott highlights the changes that have occurred since January 16th. Taken together, these amount to a revolution in the

Clovis Oncology Initiates Early Access Program for Rucaparib as Treatment and as Maintenance Therapy in Recurrent Ovarian Cancer in Europe23.3.2018 15:52Tiedote

Clovis Oncology, Inc. (NASDAQ:CLVS) today announced the initiation of an early access program in Europe for rucaparib for treatment and as maintenance therapy in recurrent ovarian cancer. The program will be overseen and implemented by Caligor Coghlan, which specializes in early access to medicines. The program, to be known as the Rucaparib Access Program (RAP), will enable participation from certain countries in Europe, where permitted by applicable rules, procedures and regulatory authorities. The RAP protocol allows for rucaparib treatment of an individual patient with third-line or greater BRCA mutant epithelial, fallopian tube, or primary peritoneal ovarian cancer who has platinum-sensitive disease and is unable to tolerate further platinum-based chemotherapy or has platinum-resistant disease and needs treatment with single agent rucaparib. The RAP protocol will also provide access to rucaparib for maintenance therapy of an individual patient with recurrent epithelial ovarian, fal

CHMP Grants Positive Opinion for Clovis Oncology’s Rubraca® (rucaparib) Tablets23.3.2018 15:50Tiedote

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the European Union’s (EU) European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a conditional marketing authorization for Rubraca as monotherapy treatment of adult patients with platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy. The European Marketing Authorization application for the treatment indication was based on objective response rate and duration of response results from two multicenter, single-arm, open-label clinical trials, Study 10 and ARIEL2, in women with advanced BRCA mutant ovarian cancer who had progressed after two or more prior chemotherapies. “The recommendation

Janssen Announces Positive CHMP Opinion for JULUCATM▼ (dolutegravir/rilpivirine)23.3.2018 15:46Tiedote

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a Positive Opinion recommending marketing authorisation for JULUCA™ (dolutegravir 50mg [ViiV Healthcare UK Ltd]/rilpivirine 25mg [Janssen Sciences Ireland UC]). Dolutegravir/rilpivirine is a single-pill, two-drug regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 c/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor (NNRTI) or integrase strand transfer inhibitor (INSTI).1 “We are delighted to be one step closer to bringing JULUCA™ to people living with HIV in Europe,” said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, LLC. “Building on our 25-year c

Aitheon Executives Educate World Leaders on Benefits, Challenges of AI at the Annual World Government Summit in Dubai23.3.2018 15:00Tiedote

Aitheon, makers of the world’s first blockchain-powered platform to solve real problems by integrating AI, robotics, IoT, human specialists and cryptocurrency, announced today that executives from the company held a series of high-level briefings with world leaders at the Annual World Government Summit in Dubai. Briefings covered the benefits and challenges of AI, and revolutionary new solutions to world challenges made possible by transformative new technologies. (Read the full release at This press release features multimedia. View the full release here: Aitheon founder and CEO, Andrew Archer, and Chief Strategy Officer, Ryan Burleson, were invited to brief leaders at the Summit by Cyrus Hodes, Co-founder and Director of the AI Initiative, an undertaking of the Future Society at Harvard University’s Kennedy School. Archer and Burleson addressed a variety of AI-related topics, including the impact of AI on

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme